Patent · US Active

Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease

US8114887B2 · kind B2 · utility

0Cited by

7References

11Claims

0Family size

Assignees

Merck Sharp & Dohme LLC · US
Sunesis Pharmaceuticals, Inc. · US

Inventors

James C. Barrow · Harleysville, US
Craig A. Coburn · Royersford, US
Melissa Egbertson · Ambler, US
Georgia B. McGaughey · Harleysville, US
Melody McWherter · Boyertown, US
Lou Anne Neilson · Sellersville, US
Kenneth E. Rittle · Lansdale, US
Harold G. Selnick · Ambler, US
Shaun R. Stauffer · Brentwood, US
Zhi-Qiang Yang · Schwenksville, US
Wenjin Yang · Foster City, US
Wanli Lu · Burlingame, US
Bruce Fahr · Foster City, US

Key dates

Filing date	Oct 12, 2005
Grant date	Feb 14, 2012
Priority date	—
Expiry date	Jun 14, 2028

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to spiropiperidine compounds of formula (I)which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.